A multicenter clinical proof of concept trial starts

Back to overview

Beginning of 2016 in Europe starts a clinical multicenter trial (NISCI) testing the efficacy of an antibody against Nogo-A in acute spinal cord injured patients. Nogo-A is known as an axon growth inhibitory protein and the study aims to test the efficacy of this antibody therapy to improve motor outcome and quality of life of tetraplegic patients. A previous phase I clinical study has shown that this treatment is safe and well tolerated. The double-blind, placebo-controlled trial will enroll patients with various degrees of complete to incomplete acute spinal cord injury.
The trial will be coordinated by a center in Switzerland, additional study centers are located in Germany, France, Italy and the Czech Republic. This European multicenter study will take 5 years and is expected to be finalized end of 2020. 

For more information please refer to: http://cordis.europa.eu/project/rcn/198795_en.html